Promotion of Coronary Collateral Function by Ivabradine-Induced Bradycardia in Patients With Coronary Artery Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

43 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-10-31

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study in patients with chronic stable coronary artery disease treatable by percutaneous coronary intervention (PCI) is to evaluate the long-term efficacy and safety of the orally taken selective I(f)-inhibitor Ivabradine (Procoralan®, Servier Switzerland) with regard to the promotion of collateral growth.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease

NCT01768585

Coronary Artery Disease Coronary Arteriosclerosis

UNKNOWN PHASE4

Ivabradine to Improve Endothelial Function in Patients With Coronary Artery Disease

NCT02681978

Coronary Artery Disease

COMPLETED PHASE4

PeRiOperaTivE CardioproTection With Ivabradine in Non-cardiac Surgery

NCT04436016

Myocardial Injury Myocardial Ischemia

COMPLETED PHASE4

Effect of Ivabradine on Heart Rate & Effort Tolerance in Mitral Stenosis in Sinus Rhythm

NCT01022463

Mitral Stenosis

COMPLETED PHASE3

Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker

NCT03830957

Heart Failure CT Angiography Ischemic Cardiomyopathy +5 more

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Coronary artery disease (CAD) is the leading cause of death in industrialized countries. Current therapies for restoration of coronary flow are percutaneous coronary intervention (PCI) or surgical revascularization. However, inherent to them are procedure-related risks and the fact that CAD progression is not prevented. Additionally, up to one fourth of all CAD patients are not amenable to standard revascularization therapies. Thus, there is a need for alternative therapies. Coronary collaterals as natural bypasses are anastomoses without an intervening capillary bed between portions of the same coronary artery or between different coronary arteries. The coronary collateral circulation is prevalent in humans and in CAD the amount of collateral flow is directly related to infarct size, all-cause- and cardiac mortality. Thus, the goal is to promote collateral function in the sense of prophylactic myocardial salvage.

Coronary (collateral) blood flow occurs almost entirely during diastole. Fluid shear stress (FSS) is the driving force in the formation, promotion and maintenance of collaterals (i.e. arteriogenesis). It is the product of blood viscosity and shear rate, the latter being the fluid velocity change between different fluid layers which is related to the fluid velocity at the endothelium. Prolongation of diastole via reduction of resting heart rate (RHR) is naturally equal to extension of shear stress at the endothelium. Bradycardia is likely to be the key factor for augmented collateral function: In several animal models, an inverse relation between heart rate and collateral function was found. We have recently confirmed this finding investigating collateral function measurements in normal coronary arteries of our patient population.

The fact that beta blockers depress contractility and unmask beta-adrenergic coronary vasoconstriction has prompted the development of selective I(f)-inhibitors. To date, ivabradine is the only clinically available specific inhibitor of the pacemaker current in the sinuatrial node (called "funny" current, because of permeability for mixed ions and activation by hyperpolarization instead of depolarization, I(f)). It acts as a pure heart rate lowering agent without affecting blood pressure, myocardial contractility, intra-cardiac conduction, or ventricular repolarization. In contrast to beta blockers or calcium channel blockers, it mimics physiological bradycardia and is therefore appropriate for the purpose of this study. By bradycardization in CAD, ischemia is targeted via reduction of myocardial oxygen demand and increase of oxygen supply without negative inotropic, coronary vasoconstrictive, or metabolic effects. In terms of anti-anginal efficacy, ivabradine has been found to be as effective as atenolol or amlodipine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Collateral promotion; PCI after 6 months

Group Type EXPERIMENTAL

Ivabradine

Intervention Type DRUG

bid administration of 5mg ivabradine (max 7.5mg) aiming to reduce resting heart rate to 60/min

Placebo

Intervention Type DRUG

bid placebo

Collateral promotion; PCI at baseline

Group Type EXPERIMENTAL

Ivabradine

Intervention Type DRUG

bid administration of 5mg ivabradine (max 7.5mg) aiming to reduce resting heart rate to 60/min

Placebo

Intervention Type DRUG

bid placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ivabradine

bid administration of 5mg ivabradine (max 7.5mg) aiming to reduce resting heart rate to 60/min

Intervention Type DRUG

Placebo

bid placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Procoralan, I(f)-inhibitor Placebo control

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age \> 18 years old
2. 1- to 3-vessel stable coronary artery disease (CAD)
3. At least 1 stenotic lesion suitable for PCI
4. No Q-wave myocardial infarction in the area undergoing CFI measurement
5. Written informed consent to participate in the study

Exclusion Criteria

1. Acute coronary syndrome
2. CAD treated best by surgical coronary bypass
3. Indications for BB treatment (heart failure, arrhythmias, \<3months post-infarct)
4. RHR \<60/min without any treatment
5. Sick sinus syndrome, sinuatrial block or \>2nd degree atrio-ventricular block
6. Atrial fibrillation
7. Inherited or acquired long-QT syndrome
8. Indwelling pacemaker
9. Severe hepatic or renal failure (creatinine clearance \<15ml/min)
10. Hypersensitivity against ivabradine or adjuvants
11. Pre-menopausal women

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No